Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392821 · ClinicalTrials.gov registry record · Phase 1
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00392821 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 78 participants.
The verdict
NCT00392821, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib. The second part is using the above determined dose of RAD001 in combination with sorafenib to see how effective these 2 drugs are against advanced kidney cancer. Participants will be asked to keep a pill diary.
Interventions
- DRUG Sorafenib
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392821
The ClinicalTrials.gov registry entry for NCT00392821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00392821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392821 about?
NCT00392821 is a clinical study titled "Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer". This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib. The second part is using the above determined dose of RAD001 in combination with sorafenib to see how effective these 2 drugs are against advanced kidney cancer. ...
What is the current status of trial NCT00392821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2006-12. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00392821?
The interventions under investigation include: Sorafenib (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00392821?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.